(Reuters) – AstraZeneca on Friday topped analyst expectations for second-quarter profit and revenue, helped by higher demand for its cancer medicines.
The London-listed company also raised its full-year revenue guidance, saying it expects it to rise by a percentage in the low twenties rather than the high teens forecast previously.
(Reporting by Natalie Grover in London; Editing by David Goodman)
